Subscribe
Close
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

ePharmaSolutions Relocated Its Headquarters To Plymouth Meeting, Pennsylvania

02/12/2014
ePharmaSolutions, a provider of eClinical solutions and specialty clinical services, relocated its headquarters to Plymouth Meeting, Pennsylvania, near Northwest Philadelphia.

The firm said its relocation was to support the 40 percent increase in headcount as a result of doubling its sales from 2012. More than 20 new customers were added to its expanding list of biopharmaceutical clients with a 50 percent increase in enterprise eClinical software sales from the previous year.

"Our new facility is twice the square footage of our previous headquarters and supports our staff growth throughout 2013 with room for continued growth over the next few years," stated Keya Watkins, ePharmaSolutions' Sr. Vice President of Operations.

The company's continued growth is attributed to refining its service offerings and re-architecting its technology into a highly scalable and self-configurable cloud-based eClinical platform, with integrated workflow "apps" that can facilitate site feasibility and activation, study training, safety letter distribution, patient recruitment, remote monitoring, and electronic trial master file.

"Clients can deploy our solution at the enterprise or study level, select the 'Apps' they want for each study, and configure a study in less than a day, making the process simple and fast for study teams to facilitate the set-up of complex global clinical trials," added Ms. Watkins.

ePharmaSolutions officials said the company reached several important goals in 2013 by launching its ReferralPlus patient recruitment program, initiating its CRO Partnership Program, and launching several new Apps to its platform. The firm also won the 2013 Microsoft Life Sciences Innovation Award, the 2013 Bio-IT World "Best In Show" Award and being profiled by CenterWatch as one of the Top 20 Innovators in the Clinical Trials Industry.

Exclusive Research